July 24, 2019

Inherited Bone Marrow Failure Syndromes as Experiments of Nature for Blood Diseases

Emerging evidence regarding the genetic pathways involved in Scwachman-Diamond syndrome and Severe Congenital Neutropenia

650×450-Corey

By Seth J. Corey, MD, MPH

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Cancer is a disease due to the acquisition of somatic mutations; it is a disease of aging. So, why do children develop cancer? That’s the question my lab has been studying by focusing on acute myeloid leukemia (AML). Less common than acute lymphoblastic leukemia (ALL) among the pediatric population, AML has a cure rate of only 50-60%. We need greater understanding of how AML arises to design more effective therapies.

We appreciate that cancer may have roots in our germline genetic constitution. This is certainly the case with the inherited bone marrow failure syndromes (IBMFS) that I study in the laboratory and manage in the clinic. Types of IBMFS include: Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, Shwachman-Diamond syndrome (SDS), Severe Congenital Neutropenia (SCN, previously known as Kostmann syndrome), GATA2 deficiency and congenital amegakaryocytic thrombocytopenia. Phenotypically, there is some variability in the period of latency to complete bone marrow failure, involvement of other organ systems and risk of transforming into AML or a solid tumor.

Experiments of nature

These disorders are “experiments of nature.” The genes for most of the IBMFS have been identified, and for each disorder, the genes belong to a particular pathway. Fanconi anemia is due to mutation in one of about two dozen genes involved in DNA double strand break repair. Diamond-Blackfan anemia is due to mutation in one of the many genes encoding a component of the ribosome. Dyskeratosis congenita results from a mutation in one of the genes involved in protecting the telomere. Less clear is the pathway involved in the inherited neutropenias (SCN and SDS) that we study. Evidence is emerging that they may result from defects in protein production, quality and trafficking.1

Advertisement

One obstacle to understanding these disorders and their complications is the rarity of each condition. The both have an incidence of approximately one in 100,000. We have turned to studying SDS in the zebrafish.2 There are advantages to studying zebrafish over mice: organogenesis is completed within 96 hours, their development is transparent, they lay hundreds of eggs at a time permitting statistical anaylsis, and they are inexpensive to maintain. Fortuitously, the similarity between human and zebrafish SDS protein is almost 90%. Using CRISPR genome editing, Usua Oyarbide, PhD, created a zebrafish model of SDS in my lab. The fish display the same features as children with SDS: small stature, neutropenia and pancreatic atrophy. Tissue analysis showed defects that are more widespread. Gene expression analysis identified a cellular stress response involving p53, sometimes referred to as the guardian of the genome. More excitingly, Dr. Oyarbide has introduced one of the mutated genes for human SDS into the fish. This will permit us to identify the additional genetic changes required to produce AML, as children with SDS have a 1,000-fold increased risk of developing AML.

Predicting clonal competition and outgrowth

Those with SCN who develop AML acquire mutations in the receptor for granulocyte colony-stimulating factor (GCSF, known as filgrastim). The mutations occur spontaneously in some children, and the high, chronic doses of filgrastim permit clones to flourish and dominate. We have identified signaling events for GCSF Receptor and the mutant forms.3-6 We have identified differences in phosphorylated proteins at early time points (less than two hours) and gene expression changes at later time points (more than two hours). We have used deep sequencing of DNA to determine mutation rates due to intracellular stress responses associated with SCN. We are correlating these biochemical and genetic events with clonal bad behavior, and developing mathematical models to predict clonal competition and outgrowth.7 With this information and machine learning, our goal is to intervene in those patients at highest risk of AML before the leukemic clones are established.

References

  1. Oyarbide U, Corey SJ. SRP54 and a Need for a New Neutropenia Nosology. Blood. 2018;132(12):1220-22.
  2. Oyarbide U, Topczewski J, Corey SJ. Peering Through Zebrafish to Understand Inherited Bone Marrow Failure Syndromes. Haematologica. 2019;104(1):13-24.
  3. Corey SJ, Burkhardt AL, Bolen JB, Gaehlen RL, Tkatch LS, Tweardy DJ. Granulocyte Colony-Stimulating Factor Receptor Signaling Involves the Formation of a Three-Component Complex With Lyn and Syk Protein-Tyrosine Kinases. Proc Natl Acad Sci U S A. 1994; 91(11):4683-7.
  4. Corey SJ, Dombrosky-Ferlan PM, Zuo S, et al. Requirement of Src Kinase Lyn for Induction of DNA Synthesis by Granulocyte Colony-Stimulating Factor. J Biol Chem. 1998;273(6):3230-5.
  5. Mehta HM, Glaubach T, Long A, et al. Granulocyte Colony-Stimulating Factor Receptor T595I (T618I) Mutation Confers Ligand Independence and Enhanced Signaling. Leukemia. 2013;27(12):2407-10.
  6. Mehta HM, Futami M, Glaubach T, et al. Alternatively Spliced, Truncated GCSF Receptor Promotes Leukemogenic Properties and Sensitivity to JAK Inhibition. Leukemia. 2014; 28(5):1041-51.
  7. Wojdyla T, Metha H, Glaubach T, et al. Mutation, Drift and Selection in Single-Driver Hematologic Malignancy: Example of Secondary Myelodysplastic Syndrome Following Treatment of Inherited Neutropenia. PLoS Comput Biol. 2019;15(1):e1006664.

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad